I have known Banks and several members of the team at Bourne Partners for many years. They understand the healthcare sector extremely well and are genuinely people of high integrity. John King, Founder and Non-executive Chairman, Warner Chilcott

I am very pleased to renew our association with the management team at Bourne Partners. We look forward to more opportunities to work with them to expand our investment opportunities and generate additional international business within our portfolio. John Gregory, Founder and Former CEO, King Pharmaceuticals

We have worked with the team at Bourne Partners over a number of years on several transactions both in Europe and the United States. Their experienced bankers provide a high level of industry knowledge and deal making expertise within the middle market healthcare arena. The firm has been an invaluable financial advisor to Desitin and we continue to utilize their group in evaluating various strategic opportunities. Martin Zentgraf, General Manager, Desitin Arzneimittel GmbH

We have worked successfully with Bourne Partners on several key projects recently, and greatly value their industry insight, advice and perseverance.Usman Of special note is their ability to simplify complex projects and maximize the value for their clients. Jeff Rowan, Chief Executive Officer, Fleet Laboratories

We are excited to partner with Bourne Capital Partners to jointly build CollMED Laboratories, a new advanced wound care business located in the United States. This is the second time we have worked with the Bourne team and look forward to future collaborations. Michael Myers, CEO, Innocoll Pharmaceuticals

We have worked with Bourne Partners since 2004, most recently as an extension of our core business development team working to license and acquire assets from US domiciled companies in the CNS category. Their hard work, in depth sector knowledge, seamless integration with our executive team and relationships within the specialty pharmaceutical market have made them a true asset to our organization.
Harald Jainta, Director of Business Development, Desitin Arzneimittel GmbH

I have worked with the team at Bourne Partners on various initiatives over the last few years. Most recently they were members of the deal team focused on closing a complex global divestiture of a gastrointestinal pharmaceutical business. Bourne Partners market knowledge, experience and strategic advice were instrumental in bringing the deal to a successful close.
Lucantonio Salvi, Partner, Sheppard Mullin Richter & Hampton LLP

We worked across the table from the team at Bourne Partners during our licensing of the European development and commercialization rights to our lead product, Sumatriptan DosePro. Their team was always professional and their bankers understood the intricacies of a cross border transaction. Bourne Partners’ expertise and diligent approach helped drive this transaction to a timely close.
Jonathan Rigby, Vice President, Business Development, Zogenix, Inc.

I had the opportunity to work closely with Banks and his team at Bourne Partners, and thoroughly enjoyed the experience. Banks and his group worked tirelessly, and demonstrated integrity and insight, throughout the assignment. It would be my pleasure to work with Bourne Partners again in the future.
Henry McCarthy, Director, Strategic Planning & Operations, GlaxoSmithKline

I have known Banks and select members of his team for more than 12 years. Banks experience in IT services/solutions as an executive with my company, coupled with Bourne Partners’ deep healthcare expertise, makes them a unique financial advisor in the space.
Michael Vadini, Chief Executive Officer, TITAN Technology Partners

Banks and his firm Bourne Partners continue to be our go to partner for strategic advisory services in the Rx Health Care space. Banks’ extensive network, creativity and passion adds great value to any potential transaction. The Bourne team is smart, responsive and available when you need them.
Steve Ruhf, Chief Business Development Officer, Fleet Laboratories

We enjoyed working with the Bourne Partners team to evaluate strategic alternatives and partnering strategies for select products in our portfolio.
Claes Thulin, Chief Executive Officer, BioPhausia AB

It is my pleasure to write this recommendation for Banks and Bourne Partners. We regularly work with industry leaders in our area of medicine. I can say unequivocally that Banks' vision, drive, and competence set him apart. When coupled with a good knowledge of the area, he is a formidable presence in the biomedical space. I would recommend him without reservation.
David Armstrong, DPM, MD, PHD, Professor of Surgery and Director, Southern Arizona Limb Salvage Alliance (SALSA) at University of Arizona

I have known Banks since business school and we worked together at Wachovia Securities. He and his team are incredibly talented and adept at managing various assignments at one time. I have found he approaches all of his client engagements with careful thoughtfulness and is very results oriented.
Tim Mages, Principal, Peachtree Equity Partners

I have worked with Banks in two separate organizations and hope to work together again in the future. Banks and his team are a high performance organization that consistently and creatively delivers value for their clients. We worked together as a corporate development team at a high-growth technology services firm and in investment banking at Wachovia Securities. His contributions were impressive, his work products excellent, and his negotiating and analytical skills formidable. I invite anyone with questions regarding Banks or his firm to contact me directly at any time for more specifics. He is a talented, rare individual.
Charles Cox, Chief Executive Officer of Cellcontrol (former Senior Vice President Morgan Keegan & Company, Inc.)

Bourne Partners was more than our investment bank, they were a value-added partner and extension of our management team. Their team members brought both a unique financial and operational perspective, were extremely professional and have unparalleled knowledge of the healthcare industry. Bourne’s investment and advisory experience, in combination with the resources they were able to bring to the table, were crucial in successfully closing our transaction with the best financial partner for Covis. Bill Collins, CEO, Covis Pharmaceuticals, Inc.

I would highly recommend Bourne Partners as a financial advisor to anyone in the healthcare industry. Unlike other advisory firms, they have actually invested in and operated other pharmaceutical companies, so they bring a unique perspective to the table. Their experience and industry insight were invaluable in bringing our transaction to fruition. Jack Davis, CEO, Covis Pharma Holdings Sarl